Monogenic Obesity; Using Drugs to Bypass the Problem
- PMID: 29972795
- DOI: 10.1016/j.cmet.2018.06.015
Monogenic Obesity; Using Drugs to Bypass the Problem
Abstract
Safe and effective pharmacological treatments for severe obesity remain scarce. In this issue of Cell Metabolism, Iepsen et al. (2018) show that obese patients with pathogenic melanocortin 4 receptor mutations, the most common form of monogenic obesity, lose weight with glucagon-like peptide 1 (GLP-1) receptor agonist therapy.
Copyright © 2018 Elsevier Inc. All rights reserved.
Comment on
-
Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.Cell Metab. 2018 Jul 3;28(1):23-32.e3. doi: 10.1016/j.cmet.2018.05.008. Epub 2018 May 31. Cell Metab. 2018. PMID: 29861388 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
